A 48-year-old woman is enrolled in a double-blind, placebo-controlled RCT evaluating a novel statin (Statin-Z) for primary prevention of coronary artery disease. She is randomized to the Statin-Z arm and receives the active drug. At 6 months, she develops severe myalgia and is diagnosed with statin-induced muscle injury (confirmed by elevated CK levels). The trial protocol mandates that all adverse events are reported to the Data Safety Monitoring Board (DSMB), but the treating physician decides *not* to report this event because he believes it is unrelated to the study drug and does not want to 'bias' the trial results. The patient continues in the trial. Which of the following is the most serious ethical and methodological consequence of this action?

Explanation

## The Core Ethical and Methodological Violation **Key Point:** The physician's failure to report a serious adverse event (SAE) to the DSMB is a breach of the fundamental duty to monitor participant safety and maintain informed consent. ## Why This Is the Most Serious Consequence ### Informed Consent Violation Informed consent requires that: 1. Participants know the **known and potential risks** of the intervention. 2. Participants can **withdraw** if new safety information emerges. 3. The research team **actively monitors** safety and reports findings. By not reporting the myalgia and elevated CK: - The participant is unaware of a serious adverse event that has occurred *in her own body*. - She cannot make an informed decision about continuing. - Other participants in the trial remain unaware of a potential safety signal. ### Breach of Safety Monitoring **High-Yield:** The DSMB exists precisely to: - Aggregate safety data across all participants. - Detect safety signals early (even if individual events seem 'unrelated'). - Recommend trial modification or termination if harm exceeds benefit. - Protect the integrity and ethics of the trial. The physician's unilateral decision to withhold information undermines this entire system. ## Why Other Options Are Secondary or Incorrect | Consequence | Why It Is Not the Primary Answer | |---|---| | **Loss of equipoise** | Equipoise refers to genuine uncertainty about which arm is superior. One adverse event does not necessarily destroy equipoise; the DSMB would assess this. The primary violation is *not reporting it so the DSMB can assess it*. | | **Performance bias** | Performance bias (differential treatment of groups due to knowledge of assignment) is a separate methodological issue. This scenario involves *concealment of safety data*, not biased treatment delivery. | | **Failure of beneficence** | While beneficence (acting in the participant's best interest) is relevant, the most direct and serious violation is the breach of informed consent and safety monitoring. | ## Regulatory and Legal Framework **Clinical Pearl:** Under ICH-GCP guidelines and Indian ICMR regulations: - All serious adverse events must be reported to the DSMB and ethics committee. - The physician cannot unilaterally decide an event is 'unrelated' and withhold it. - Failure to report is grounds for trial termination and investigator sanctions. ## Correct Approach **Mnemonic: SAE Reporting (REPORT):** - **R**eport immediately to DSMB - **E**valuate causality (not the physician's solo judgment) - **P**rotect participant autonomy (inform her) - **O**pen communication with ethics committee - **R**eview trial safety profile - **T**erminate if benefit-risk ratio is unfavorable